Last reviewed 2026-04-20 · How we verify

MIDOMAFETAMINE HYDROCHLORIDE

Phase 1 active Small molecule Quality 15/100

MIDOMAFETAMINE HYDROCHLORIDE is a drug. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MIDOMAFETAMINE HYDROCHLORIDE
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Headache
Nausea
Insomnia
Anxiety
Fatigue
Muscle Tightness
Muscle tightness
Suicidal ideation
Dizziness
Hyperhidrosis
Suicidal Ideation
Decreased Appetite

Key clinical trials

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study) (PHASE2)
Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial (PHASE2)
MDMA Plus Exposure Therapy for PTSD (PHASE2)
MDMA-Assisted Massed Exposure Therapy for PTSD (PHASE2)
MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD (PHASE3)
High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD (PHASE2)
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD (PHASE2)
Group MDMA-therapy for Veterans With PTSD (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MIDOMAFETAMINE HYDROCHLORIDE CI brief — competitive landscape report
MIDOMAFETAMINE HYDROCHLORIDE updates RSS · CI watch RSS

Frequently asked questions about MIDOMAFETAMINE HYDROCHLORIDE

What is MIDOMAFETAMINE HYDROCHLORIDE?

MIDOMAFETAMINE HYDROCHLORIDE is a Small molecule drug.

What development phase is MIDOMAFETAMINE HYDROCHLORIDE in?

MIDOMAFETAMINE HYDROCHLORIDE is in Phase 1.

What are the side effects of MIDOMAFETAMINE HYDROCHLORIDE?

Common side effects of MIDOMAFETAMINE HYDROCHLORIDE include Headache, Nausea, Insomnia, Anxiety, Fatigue, Muscle Tightness.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing